Skip to main content
TipRanks
Go Ultimate75% OFF

Prestige Consumer Healthcare (PBH) AI Stock Analysis

124 Followers
PBH

Prestige Consumer Healthcare

(NYSE:PBH)

Select Model
Rating:65Neutral
Price Target:$52.00â–²(7.84% Upside)
Action:downgraded
Date:11/06/26

PBH scores as moderately attractive mainly due to solid underlying profitability and cash generation, supported by reasonable valuation. The score is held back by weak technicals (price below key moving averages) and earnings-call risks tied to Clear Eyes supply volatility, higher interest expense, and elevated leverage despite generally positive operating/acquisition momentum.

Positive Factors
Strong cash generationRobust operating and free cash flow indicates that reported earnings are converting into funds available for debt reduction, reinvestment, and brand support. This provides financial resilience and should help sustain the portfolio strategy even as recent cash-flow growth has softened.
Negative Factors
Clear Eyes production disruptionClear Eyes production volatility is a material operational drag because zero safety stock caused disruption to reach sales immediately. Remediation requires multiple actions and sterile-manufacturing changes may take time, limiting near-term recovery and brand contribution.

Prestige Consumer Healthcare (PBH) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%PBH-18.51%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.29B
Dividend Yield
―
Average Volume (3M)
573.57K
Price to Earnings (P/E)
14.9
Beta (1Y)
0.44
Revenue Growth
5.10%
EPS Growth
-19.73%
Country
US
Employees
890
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Prestige Consumer Healthcare Business Overview & Revenue Model

Company Description

Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's...

How the Company Makes Money

Prestige Consumer Healthcare primarily makes money by selling branded OTC consumer healthcare products to retailers and distributors, recognizing revenue when control of products transfers under its customer arrangements. Its key revenue streams are...

Prestige Consumer Healthcare Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q2-2027)|% Change Since:-9.50%|Next Earnings Date:Feb 04, 2027
Earnings Call SentimentPositive

The call was predominantly positive: the company exceeded second-quarter sales and earnings expectations, reported strong profitability, maintained healthy base-business consumption trends, and described both acquisitions as performing well. eCommerce, key GI brands, international brands, and long-term Clear Eyes opportunities were also highlighted. The principal negative was Clear Eyes production volatility, which reduced the full-year outlook and limited near-term sales, while working-capital timing and higher interest expense pressured cash flow and EPS. Overall, the positive operating and acquisition trends significantly outweighed the identified challenges.

Positive Updates

Second-Quarter Revenue and Earnings Beat
Management reported that second-quarter sales and earnings exceeded expectations. Revenue was $336.3 million, up 22.7% from $274.1 million, reflecting the first full quarter of ownership of the Breathe Right and LaCorium portfolios. Adjusted diluted EPS was $1.13, up approximately 6% versus the prior year.

Negative Updates

Clear Eyes Production Volatility Reduced the Outlook
Production volatility began in late September and continued into October, leading the company to adjust its fiscal 2027 outlook. With zero safety-stock availability, the impact was felt immediately. Management is now forecasting less than $20 million of Clear Eyes sales for the full year, with limited improvement expected in the second half.

Company Guidance

For fiscal 2027, the company now expects full-year revenue of $1.28 billion-$1.29 billion, which equates to about 2% organic growth, excluding Clear Eyes, including approximately $190 million of revenue from Breathe Right and LaCorium; Clear Eyes sales are now forecast at less than $20 million for the full year, with limited improvement in the second half expected. Q3 revenue is expected to be approximately $328 million, with organic revenue decreasing year-over-year, and adjusted diluted EPS is expected to be $4.48-$4.55 for the full year and $1.05 for Q3. The company expects adjusted gross margin of just over 57% for the full year and just over 58% gross margin for the remainder of the year, an A&M rate of approximately 14.5% of sales, adjusted G&A of approximately 10% as a percent of sales, interest expense of approximately $104 million, amortization expense of $32 million, adjusted free cash flow of $265 million or more, and a year-end leverage ratio of approximately four times; long-term CapEx is expected to be 1%-3% of sales, with the company taking a look at $26 million for this year.

Prestige Consumer Healthcare Financial Statement Overview

Summary

Financials are solid overall: strong profitability and cash generation (healthy margins and robust free cash flow with good conversion), offset by modest longer-term revenue growth, recent softening in free-cash-flow growth, and some uncertainty/volatility in leverage and prior-period results.

Income Statement

76Positive

Balance Sheet

70Positive

Cash Flow

73Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.17B1.09B1.14B1.13B1.13B1.09B
Gross Profit606.96M574.64M634.46M624.45M625.29M620.65M
EBITDA315.31M331.11M361.99M373.86M7.87M358.84M
Net Income155.10M190.30M214.60M209.34M-82.31M205.38M
Balance Sheet
Total Assets4.72B3.55B3.40B3.32B3.35B3.67B
Cash, Cash Equivalents and Short-Term Investments46.52M63.87M97.88M46.47M58.49M27.18M
Total Debt2.12B1.05B1.04B1.14B1.37B1.51B
Total Liabilities2.78B1.66B1.57B1.66B1.91B2.09B
Stockholders Equity1.94B1.89B1.83B1.66B1.45B1.58B
Cash Flow
Free Cash Flow214.22M246.45M243.29M239.38M221.93M250.28M
Operating Cash Flow229.78M257.63M251.51M248.93M229.72M259.92M
Investing Cash Flow-1.33B-136.84M-17.45M-20.11M-11.58M-256.51M
Financing Cash Flow1.03B-156.06M-182.07M-241.01M-185.85M-7.57M

Prestige Consumer Healthcare Technical Analysis

Technical Analysis SentimentPositive
Last Price48.22

Price Trends

50DMA47.29Positive
100DMA49.02Negative
200DMA52.98Negative

Market Momentum

MACD-0.45Negative
RSI52.93Neutral
STOCH54.02Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBH, the sentiment is Positive. The current price of 48.22 is above the 20-day moving average (MA) of 47.34, above the 50-day MA of 47.29, and below the 200-day MA of 52.98, indicating a neutral trend. The MACD of -0.45 indicates Negative momentum. The RSI at 52.93 is Neutral, neither overbought nor oversold. The STOCH value of 54.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBH.

Prestige Consumer Healthcare Risk Analysis

Prestige Consumer Healthcare disclosed 25 risk factors in its most recent earnings report. Prestige Consumer Healthcare reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.The use of artificial intelligence technologies presents operational, legal and regulatory risks.Q1, 2026
2.We are subject to complex and evolving data privacy, data protection and data security laws, and failure to comply could result in significant costs, liabilities and operational restrictions.Q1, 2026
3.Our current indebtedness could adversely affect our financial condition and we may incur substantially more debt in the future.Q1, 2025

Prestige Consumer Healthcare Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PBH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PBHPBH65Neutral$2.29B14.878.19%―5.10%-19.73%
SCYXSCYX53Neutral$28.37M-2.44-18.65%―543.96%72.49%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BFRIBFRI43Neutral$10.65M-1.48-110.30%―29.85%78.56%
COSMCOSM38Underperform$14.34M-0.22-118.89%―33.82%34.05%
NSRXNSRX29Underperform$30.57M-2.54-158.83%―――

* Healthcare Sector Average

Performance Comparison

-50%0%50%PBHSCYXCOSMBFRINSRXCUVLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PBH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PBHPrestige Consumer Healthcare48.22-10.27-17.56%
SCYXSCYNEXIS Inc2.85-1.87-39.62%
COSMCosmos Holdings 2.85-10.13-78.05%
BFRIBiofrontera, Inc.0.59-0.22-26.70%
NSRXNasus Pharma Ltd.2.61-4.39-62.71%
CUVLClinuvel Pharmaceuticals Limited Sponsored ADR4.90-2.10-30.03%

Prestige Consumer Healthcare Corporate Events

Financial DisclosuresM&A Transactions

Prestige Consumer Healthcare Reports Fiscal 2027 Second-Quarter Results

Positive
Nov 5, 2026

Prestige Consumer Healthcare, an over-the-counter healthcare company serving North American and international markets, reported fiscal 2027 second-quarter and first-half results on November 5, 2026. Its portfolio included consumer health brands such...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026